Challenges With Buprenorphine Initiation in the Fentanyl Era—Adapting Effectively to the Moment
JAMA Network Open · 05.01.2026 · 9 (1) · e2552140
DOI: 10.1001/jamanetworkopen.2025.52140 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 05.01.2026. Verfasst von William M Garneau und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Division of Hospital Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 7 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDA NIH HHS.
Abstract (Originalsprache)
Current best practice for management of opioid use disorder (OUD) includes provision of medication with full (eg, methadone) or partial (eg, buprenorphine) activity at the μ opioid receptors. Buprenorphine is extensively used to treat OUD, and has long been noted to have the capacity to precipitate opioid withdrawal with initial dosing. 1 In this study, Kawasaki et al 2 share data from a nationwide survey of buprenorphine prescribers reporting challenges with buprenorphine-related withdrawal in the current era of nonpharmaceutical fentanyl (NPF) use. 2 These findings are timely and illustrate the complexity of contemporary treatment of OUD. The reported incidence of buprenorphine initiation–related precipitated withdrawal (PW) in the era of fentanyl has varied widely. A nationwide clinical trial of emergency department– initiated buprenorphine reported a less than 1% incidence of PW, while other recent accounts have included rates of more than 10%. 3,4 In this study, Kawasaki et al 2 report the findings of a 2023 to 2024 nationally representative survey of 396 US buprenorphine prescribers. The study population included physicians and advanced practice clinicians who initiated at least 10 patients with OUD onto buprenorphine during the prior year and at least 1 in the past 90 days. The survey included 96 questions covering clinician demographics,
Autor:innen und Institutionen
- Department of Medicine, Division of Hospital Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
- Behavioral Pharmacology Research Unit, Department of Psychiatry and Behavioral Sciences, Johns Hopkins University School of Medicine, Baltimore, Maryland.
- Department of Medicine, Division of Addiction Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland.
Förderung
- NIDA NIH HHS
Zitieren
APA
Garneau, W. M., Strain, E. C., & Fingerhood, M. I. (2026). Challenges With Buprenorphine Initiation in the Fentanyl Era—Adapting Effectively to the Moment. JAMA Network Open, 9(1), e2552140. https://doi.org/10.1001/jamanetworkopen.2025.52140
Vancouver
Garneau WM, Strain EC, Fingerhood MI. Challenges With Buprenorphine Initiation in the Fentanyl Era—Adapting Effectively to the Moment. JAMA Network Open. 2026;9(1):e2552140. doi:10.1001/jamanetworkopen.2025.52140
BibTeX
@article{Garneau2026,
author = {Garneau, William M and Strain, Eric C and Fingerhood, Michael I},
title = {Challenges With Buprenorphine Initiation in the Fentanyl Era—Adapting Effectively to the Moment},
journal = {JAMA Network Open},
year = {2026},
volume = {9},
number = {1},
pages = {e2552140},
doi = {10.1001/jamanetworkopen.2025.52140}
}
EUVIMED